A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 Aug 2024 Planned primary completion date changed from 5 Jul 2024 to 31 Aug 2024.
- 30 Jan 2024 Planned End Date changed from 8 Sep 2023 to 4 Jul 2025.
- 30 Jan 2024 Planned primary completion date changed from 8 Sep 2023 to 5 Jul 2024.